Trials / Completed
CompletedNCT03923634
Princess® RICH for the Correction of Fine Lines
A Prospective Open-label, Multicenter Study Evaluating Princess® RICH in Correction of Fine Lines
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Croma-Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline visit and at week 3 and 6.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Princess® RICH | Princess® RICH is injected into lateral canthal lines and/or perioral rhytids |
Timeline
- Start date
- 2018-10-16
- Primary completion
- 2019-04-29
- Completion
- 2019-10-22
- First posted
- 2019-04-22
- Last updated
- 2024-12-10
Locations
3 sites across 1 country: Austria
Source: ClinicalTrials.gov record NCT03923634. Inclusion in this directory is not an endorsement.